Drugs / NMS-03597812
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06549790 | Oct 2024 → Sep 2029 expected | acute myeloid leukemia | Nerviano Medical Sciences | Recruiting | No outcome recorded |
| Phase 1 | NCT05027594 | Sep 2022 → Aug 2023 | plasma cell myeloma | Nerviano Medical Sciences | Terminated | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NMS-03597812 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05027594 ↗ |
| Action | Inhibit | “A Phase I Dose Escalation Study of NMS-03597812, a PERK Inhibitor, in Adult Patients With Relapsed or Refractory Multiple Myeloma” NCT05027594 ↗ |
| Route | Oral | “NMS-03597812 administered orally once daily on Days 1-21” NCT05027594 ↗ |